BIOXCEL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.63 USD | +0.77% |
|
-4.36% | -10.85% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 263.5 | 1,126 | 568.8 | 601.9 | 86.35 | 97.4 | - | - |
| Enterprise Value (EV) 1 | 231.1 | 912.7 | 335.9 | 501.3 | 122.2 | 222.5 | 212 | 201 |
| P/E ratio | -7.23 x | -12.2 x | -5.02 x | -3.63 x | -0.48 x | -0.95 x | -1.5 x | -2.59 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 1,605 x | 62.6 x | 28.2 x | 10.7 x | 4.69 x |
| EV / Revenue | - | - | - | 1,337 x | 88.5 x | 64.5 x | 23.2 x | 9.68 x |
| EV / EBITDA | -6.91 x | -11.1 x | -3.15 x | -3.15 x | -0.71 x | -2.53 x | -2.54 x | -4.09 x |
| EV / FCF | -8.21 x | -13.7 x | -4.07 x | -3.7 x | -0.79 x | -2.64 x | -3.12 x | -3.94 x |
| FCF Yield | -12.2% | -7.3% | -24.6% | -27% | -127% | -37.8% | -32% | -25.4% |
| Price to Book | 8.85 x | 5.46 x | 2.57 x | 7.88 x | -1.52 x | -0.64 x | -1.16 x | -1.3 x |
| Nbr of stocks (in thousands) | 18,035 | 24,368 | 27,980 | 28,023 | 29,273 | 37,035 | - | - |
| Reference price 2 | 14.61 | 46.20 | 20.33 | 21.48 | 2.950 | 2.630 | 2.630 | 2.630 |
| Announcement Date | 3/9/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 0.375 | 1.38 | 3.449 | 9.133 | 20.76 |
| EBITDA 1 | -33.44 | -82.11 | -106.6 | -159.3 | -171.7 | -87.79 | -83.43 | -49.12 |
| EBIT 1 | -33.6 | -82.3 | -106.9 | -159.6 | -171.8 | -91.94 | -82.86 | -57.69 |
| Operating Margin | - | - | - | -42,572% | -12,447.97% | -2,665.67% | -907.21% | -277.9% |
| Earnings before Tax (EBT) 1 | -32.97 | -82.17 | -106.9 | -165.8 | -179.1 | -97.4 | -84.11 | -65.8 |
| Net income 1 | -32.97 | -82.17 | -106.9 | -165.8 | -179.1 | -97.4 | -83.77 | -64.67 |
| Net margin | - | - | - | -44,201.87% | -12,974.86% | -2,823.87% | -917.22% | -311.51% |
| EPS 2 | -2.020 | -3.790 | -4.050 | -5.920 | -6.150 | -2.777 | -1.759 | -1.014 |
| Free Cash Flow 1 | -28.15 | -66.67 | -82.6 | -135.5 | -155 | -84.2 | -67.9 | -51.05 |
| FCF margin | - | - | - | -36,128% | -11,233.77% | -2,441.27% | -743.45% | -245.91% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.137 | 0.238 | 0.206 | 0.457 | 0.341 | 0.376 | 0.6326 | 0.7086 | 0.8404 | 0.9372 | 1 |
| EBITDA 1 | -26.74 | -26.06 | -31.4 | -36.2 | -38.9 | -52.81 | -51.12 | -52.33 | -48.22 | -19.56 | -19.76 | -21.68 | -23.61 | -25.97 | - |
| EBIT 1 | -26.81 | -26.13 | -31.48 | -36.29 | -38.99 | -52.89 | -51.2 | -52.41 | -48.3 | -19.88 | -20.09 | -22.14 | -23.62 | -25.38 | - |
| Operating Margin | - | - | - | - | -28,459.85% | -22,224.37% | -24,853.4% | -11,469.15% | -14,163.34% | -5,285.9% | -3,176.53% | -3,124.48% | -2,810.55% | -2,707.97% | - |
| Earnings before Tax (EBT) 1 | -26.81 | -26.12 | -31.47 | -37.67 | -41.8 | -54.81 | -52.8 | -53.52 | -50.49 | -22.26 | -22.87 | -24.34 | -26.11 | -26.9 | - |
| Net income 1 | -26.81 | -26.12 | -31.47 | -37.67 | -41.8 | -54.81 | -52.8 | -53.52 | -50.49 | -22.26 | -22.87 | -24.34 | -26.11 | -26.9 | - |
| Net margin | - | - | - | - | -30,514.6% | -23,028.57% | -25,629.13% | -11,710.07% | -14,805.28% | -5,919.15% | -3,615.29% | -3,434.66% | -3,107.21% | -2,870.63% | - |
| EPS 2 | -0.9600 | -0.9300 | -1.120 | -1.350 | -1.490 | -1.950 | -1.840 | -1.830 | -1.720 | -0.7600 | -0.7487 | -0.7870 | -0.6844 | -0.7235 | -0.5100 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/10/22 | 5/9/22 | 8/9/22 | 11/10/22 | 3/9/23 | 5/9/23 | 8/14/23 | 11/14/23 | 3/12/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 35.8 | 125 | 115 | 104 |
| Net Cash position 1 | 32.4 | 213 | 233 | 101 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.2086 x | -1.425 x | -1.374 x | -2.109 x |
| Free Cash Flow 1 | -28.2 | -66.7 | -82.6 | -135 | -155 | -84.2 | -67.9 | -51.1 |
| ROE (net income / shareholders' equity) | - | -70.4% | -49.9% | -111% | -1,726% | 104% | 76.7% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 1.650 | 8.470 | 7.920 | 2.730 | -1.940 | -4.110 | -2.270 | -2.030 |
| Cash Flow per Share 2 | -1.670 | -3.060 | -3.120 | -4.830 | -5.320 | -2.080 | -1.120 | -0.4300 |
| Capex 1 | 0.87 | 0.32 | 0.45 | 0.14 | 0.02 | 0.71 | 1.77 | 1.92 |
| Capex / Sales | - | - | - | 37.07% | 1.45% | 20.63% | 19.39% | 9.25% |
| Announcement Date | 3/9/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.63
USD
Average target price
7.25
USD
Spread / Average Target
+175.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.85% | 97.4M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BTAI Stock
- Financials BioXcel Therapeutics, Inc.
